Researchers discover a paradox: high cognitive performance predicts depressive relapse, contradicting traditional expectations.
Just The News on MSN
FDA approves three fast-track studies of psychedelic drugs to treat PTSD, depression
The FDA did not specify what companies will conduct the research, but two of the companies are studying psilocybin. The third ...
Read more about LLMs show strong potential in early detection of depression in social media posts on Devdiscourse ...
Individuals with ADHD and comorbid substance use disorder were more likely to discontinue medication and less likely to resume therapy.
Apr 20, 2026 On the morning of Saturday, April 18, 2026, President Donald Trump signed an executive order (EO), Accelerating ...
Morning Overview on MSN
FDA to fast-track reviews of 3 psychedelic drugs after Trump directive
The FDA will put three psychedelic drug programs on an ultra-fast approval track, compressing review timelines from roughly ...
For the first quarter of 2026, Aristotle Capital’s International Equity ADR WM Composite posted a total return of -3.39% ...
Otsuka Holdings, a leading Japanese healthcare company, was also a top contributor to performance during the quarter. Read ...
Mamamia on MSN
Thousands of women suffer from this life-changing condition. It's a "blind spot" in Australian medicine.
Picture this: Every month, like clockwork, a dark cloud settles over you. Your brain is foggy, your mind is racing, and your ...
What social risk factors affecting your patients may affect their risk of major depressive disorder more than they realize?
Major depressive disorder (MDD) and bipolar disorder are among the leading causes of disability worldwide. However, their pathophysiological mechanisms ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results